Zeitschriftenartikel zum Thema „Pneumonic Tularemia“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Pneumonic Tularemia" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Ellis, Jill, Petra C. F. Oyston, Michael Green und Richard W. Titball. „Tularemia“. Clinical Microbiology Reviews 15, Nr. 4 (Oktober 2002): 631–46. http://dx.doi.org/10.1128/cmr.15.4.631-646.2002.
Der volle Inhalt der QuelleHORN, M., und L. ZICKUHR. „PNEUMONIC TULAREMIA: A CASE PRESENTATION“. Chest 161, Nr. 6 (Juni 2022): A142. http://dx.doi.org/10.1016/j.chest.2021.12.174.
Der volle Inhalt der QuelleGregory, Stephen H., Stephanie Mott, Jennifer Phung, Jinhee Lee, Leonard Moise, Julie A. McMurry, William Martin und Anne S. De Groot. „Epitope-based vaccination against pneumonic tularemia“. Vaccine 27, Nr. 39 (August 2009): 5299–306. http://dx.doi.org/10.1016/j.vaccine.2009.06.101.
Der volle Inhalt der QuelleBonnier, Alyssa, Santu Saha, Adam Austin und Biplab K. Saha. „An Unusual Etiology of Fluorodeoxyglucose Avid Intrathoracic Lymph Nodes“. Prague Medical Report 125, Nr. 1 (2024): 79–86. http://dx.doi.org/10.14712/23362936.2024.8.
Der volle Inhalt der QuelleNicol, McKayla J., David R. Williamson, David E. Place und Girish S. Kirimanjeswara. „Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development“. Microorganisms 9, Nr. 5 (30.04.2021): 973. http://dx.doi.org/10.3390/microorganisms9050973.
Der volle Inhalt der QuelleNelson, Christina A., Jessica Winberg, Taylor D. Bostic, K. Meryl Davis und Shannon Fleck-Derderian. „Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023“. Clinical Infectious Diseases 78, Supplement_1 (31.01.2024): S15—S28. http://dx.doi.org/10.1093/cid/ciad736.
Der volle Inhalt der QuelleJacobs, Richard F., Yoland M. Condrey und Terry Yamauchi. „Tularemia in Adults and Children: A Changing Presentation“. Pediatrics 76, Nr. 5 (01.11.1985): 818–22. http://dx.doi.org/10.1542/peds.76.5.818.
Der volle Inhalt der QuelleLovchik, Julie A., Douglas S. Reed, Julie A. Hutt, Fangfang Xia, Rick L. Stevens, Thero Modise, Eileen M. Barry und Terry H. Wu. „Identification of an Attenuated Substrain of Francisella tularensis SCHU S4 by Phenotypic and Genotypic Analyses“. Pathogens 10, Nr. 6 (22.05.2021): 638. http://dx.doi.org/10.3390/pathogens10060638.
Der volle Inhalt der QuelleWilliams, Mark S. „Efficacy of Doxycycline and Ciprofloxacin for Treatment of Pneumonic Tularemia in Cynomolgus Macaques“. Clinical Infectious Diseases 78, Supplement_1 (31.01.2024): S7—S14. http://dx.doi.org/10.1093/cid/ciad668.
Der volle Inhalt der QuelleHahn, Mark M., Cheryl A. Triplett, Michael S. Anderson, Jennifer I. Smart, Karine Litherland, Stephen Keech, Franziska von Siebenthal, Mark Jones, Andrew J. Phipps und Lisa N. Henning. „Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia“. Antibiotics 12, Nr. 8 (19.08.2023): 1337. http://dx.doi.org/10.3390/antibiotics12081337.
Der volle Inhalt der QuelleMIR, MAHNOOR, und CHRISTOPHER DAYTON. „A CASE OF PNEUMONIC TULAREMIA MIMICKING COVID-19“. Chest 160, Nr. 4 (Oktober 2021): A373. http://dx.doi.org/10.1016/j.chest.2021.07.374.
Der volle Inhalt der QuelleMaranan, Melinda C., Deborah Schiff, Daniel C. Johnson, Cyril Abrahams, Mark Wylam und Susan I. Gerber. „Pneumonic Tularemia in a Patient with Chronic Granulomatous Disease“. Clinical Infectious Diseases 25, Nr. 3 (September 1997): 630–33. http://dx.doi.org/10.1086/513777.
Der volle Inhalt der QuelleFeldman, Katherine A., Russell E. Enscore, Sarah L. Lathrop, Bela T. Matyas, Michael McGuill, Martin E. Schriefer, Donna Stiles-Enos, David T. Dennis, Lyle R. Petersen und Edward B. Hayes. „An Outbreak of Primary Pneumonic Tularemia on Martha's Vineyard“. New England Journal of Medicine 345, Nr. 22 (29.11.2001): 1601–6. http://dx.doi.org/10.1056/nejmoa011374.
Der volle Inhalt der QuelleFrick, Ondraya M., Virginia A. Livingston, Chris A. Whitehouse, Sarah L. Norris, Derron A. Alves, Paul R. Facemire, Douglas S. Reed und Aysegul Nalca. „The Natural History of Aerosolized Francisella tularensis Infection in Cynomolgus Macaques“. Pathogens 10, Nr. 5 (13.05.2021): 597. http://dx.doi.org/10.3390/pathogens10050597.
Der volle Inhalt der QuellePeriasamy, Sivakumar, Timothy Sellati und Jonathan Harton. „Lung infiltrates containing myeloid-derived suppressor cells impair protective immunity in pneumonic tularemia caused by Francisella tularemia (P3082)“. Journal of Immunology 190, Nr. 1_Supplement (01.05.2013): 187.14. http://dx.doi.org/10.4049/jimmunol.190.supp.187.14.
Der volle Inhalt der QuelleCowley, Siobhán C. „Editorial: Proinflammatory cytokines in pneumonic tularemia: too much too late?“ Journal of Leukocyte Biology 86, Nr. 3 (September 2009): 469–70. http://dx.doi.org/10.1189/jlb.0309119.
Der volle Inhalt der QuelleMATYAS, B. T., H. S. NIEDER und S. R. TELFORD. „Pneumonic Tularemia on Martha's Vineyard: Clinical, Epidemiologic, and Ecological Characteristics“. Annals of the New York Academy of Sciences 1105, Nr. 1 (29.03.2007): 351–77. http://dx.doi.org/10.1196/annals.1409.013.
Der volle Inhalt der Quelle&NA;. „AN OUTBREAK OF PRIMARY PNEUMONIC TULAREMIA ON MARTHA???S VINEYARD“. Infectious Diseases in Clinical Practice 11, Nr. 1 (Januar 2002): 39. http://dx.doi.org/10.1097/00019048-200201000-00019.
Der volle Inhalt der QuelleReed, Douglas S., Emily Olsen, Jennifer Bowling, Katherine Willett, Karsten Hazlett und Eileen Barry. „Role of antibody in vaccine-mediated protection against pneumonic tularemia in the rabbit model“. Journal of Immunology 204, Nr. 1_Supplement (01.05.2020): 168.12. http://dx.doi.org/10.4049/jimmunol.204.supp.168.12.
Der volle Inhalt der QuelleBrunet, Camille D., Aurélie Hennebique, Julien Peyroux, Isabelle Pelloux, Yvan Caspar und Max Maurin. „Presence of Francisella tularensis subsp. holarctica DNA in the Aquatic Environment in France“. Microorganisms 9, Nr. 7 (28.06.2021): 1398. http://dx.doi.org/10.3390/microorganisms9071398.
Der volle Inhalt der QuelleMalik, Salma, Vishesh Paul, Thara Damodaran, Deepa Prabakhar, Amir Khan und Sharjeel Ahmad. „648. Rapid, Non-invasive Detection of Cryptic Tularemia Using a Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing Test“. Open Forum Infectious Diseases 8, Supplement_1 (01.11.2021): S426. http://dx.doi.org/10.1093/ofid/ofab466.845.
Der volle Inhalt der QuelleLembo, Annalisa, Mark Pelletier, Ravi Iyer, Michele Timko, Jan C. Dudda, T. Eoin West, Christopher B. Wilson, Adeline M. Hajjar und Shawn J. Skerrett. „Administration of a Synthetic TLR4 Agonist Protects Mice from Pneumonic Tularemia“. Journal of Immunology 180, Nr. 11 (19.05.2008): 7574–81. http://dx.doi.org/10.4049/jimmunol.180.11.7574.
Der volle Inhalt der QuelleChang, Yie-Hwa, Duc M. Duong, Johannes B. Goll, David C. Wood, Travis L. Jensen, Luming Yin, Casey E. Gelber et al. „Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine“. Vaccines 8, Nr. 3 (24.07.2020): 413. http://dx.doi.org/10.3390/vaccines8030413.
Der volle Inhalt der QuelleWu, Terry H., Julie A. Hutt, Kristin A. Garrison, Lyudmila S. Berliba, Yan Zhou und C. Rick Lyons. „Intranasal Vaccination Induces Protective Immunity against Intranasal Infection with Virulent Francisella tularensis Biovar A“. Infection and Immunity 73, Nr. 5 (Mai 2005): 2644–54. http://dx.doi.org/10.1128/iai.73.5.2644-2654.2005.
Der volle Inhalt der QuelleMalik, Meenakshi, Chandra Shekhar Bakshi, Bikash Sahay, Aaloki Shah, Steven A. Lotz und Timothy J. Sellati. „Toll-Like Receptor 2 Is Required for Control of Pulmonary Infection with Francisella tularensis“. Infection and Immunity 74, Nr. 6 (Juni 2006): 3657–62. http://dx.doi.org/10.1128/iai.02030-05.
Der volle Inhalt der QuelleHUSNA, ASHMA UL, MUNISH R ADHIKARI, DIVYA KHAREL, YAN JIANG und GREGORY POLCHA. „UNDERSTANDING THE NEED FOR A BROAD DIFFERENTIAL DIAGNOSIS: A CASE OF PNEUMONIC TULAREMIA“. Chest 162, Nr. 4 (Oktober 2022): A560. http://dx.doi.org/10.1016/j.chest.2022.08.434.
Der volle Inhalt der QuelleBossi, P., A. Tegnell, A. Baka, F. van Loock, A. Werner, J. Hendriks, H. Maidhof und G. Gouvras. „Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia“. Eurosurveillance 9, Nr. 12 (01.12.2004): 27–28. http://dx.doi.org/10.2807/esm.09.12.00503-en.
Der volle Inhalt der QuelleRay, Heather J., Yu Cong, Ashlesh K. Murthy, Dale M. Selby, Karl E. Klose, Jeffrey R. Barker, M. Neal Guentzel und Bernard P. Arulanandam. „Oral Live Vaccine Strain-Induced Protective Immunity against Pulmonary Francisella tularensis Challenge Is Mediated by CD4+ T Cells and Antibodies, Including Immunoglobulin A“. Clinical and Vaccine Immunology 16, Nr. 4 (11.02.2009): 444–52. http://dx.doi.org/10.1128/cvi.00405-08.
Der volle Inhalt der QuelleDembek, Z. F., R. L. Buckman, S. K. Fowler und J. L. Hadler. „Missed Sentinel Case of Naturally Occurring Pneumonic Tularemia Outbreak: Lessons for Detection of Bioterrorism“. Journal of the American Board of Family Medicine 16, Nr. 4 (01.07.2003): 339–42. http://dx.doi.org/10.3122/jabfm.16.4.339.
Der volle Inhalt der QuelleYaglom, Hayley, Edwin Rodriguez, Marlene Gaither, Mare Schumacher, Natalie Kwit, Christina Nelson, Joel Terriquez et al. „Notes from the Field: Fatal Pneumonic Tularemia Associated with Dog Exposure — Arizona, June 2016“. MMWR. Morbidity and Mortality Weekly Report 66, Nr. 33 (25.08.2017): 891. http://dx.doi.org/10.15585/mmwr.mm6633a5.
Der volle Inhalt der QuelleRusso, Brian C., Joseph Horzempa, Dawn M. O'Dee, Deanna M. Schmitt, Matthew J. Brown, Paul E. Carlson, Ramnik J. Xavier und Gerard J. Nau. „A Francisella tularensis Locus Required for Spermine Responsiveness Is Necessary for Virulence“. Infection and Immunity 79, Nr. 9 (13.06.2011): 3665–76. http://dx.doi.org/10.1128/iai.00135-11.
Der volle Inhalt der QuelleAnderson, Rebecca V., Deborah D. Crane und Catharine M. Bosio. „Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs“. Vaccine 28, Nr. 40 (September 2010): 6562–72. http://dx.doi.org/10.1016/j.vaccine.2010.07.072.
Der volle Inhalt der QuelleSanapala, Shilpa, Jieh-Juen Yu, Ashlesh K. Murthy, Weidang Li, M. Neal Guentzel, James P. Chambers, Karl E. Klose und Bernard P. Arulanandam. „Perforin- and Granzyme-Mediated Cytotoxic Effector Functions Are Essential for Protection against Francisella tularensis following Vaccination by the Defined F. tularensis subsp. novicida ΔfopCVaccine Strain“. Infection and Immunity 80, Nr. 6 (09.04.2012): 2177–85. http://dx.doi.org/10.1128/iai.00036-12.
Der volle Inhalt der QuelleReed, Douglas S., Le'Kneitah Smith, Tammy Dunsmore, Anita Trichel, Luis A. Ortiz, Kelly Stefano Cole und Eileen Barry. „Pneumonic Tularemia in Rabbits Resembles the Human Disease as Illustrated by Radiographic and Hematological Changes after Infection“. PLoS ONE 6, Nr. 9 (13.09.2011): e24654. http://dx.doi.org/10.1371/journal.pone.0024654.
Der volle Inhalt der QuelleSchmitt, Deanna, Dawn O'Dee, Matthew Brown, Jospeh Horzempa, Brian Russo und Gerard Nau. „IL-15/IL-15Rα improves immune cell survival but does not reduce disease severity following pulmonary infection with the intracellular bacterium Francisella tularensis (56.27)“. Journal of Immunology 186, Nr. 1_Supplement (01.04.2011): 56.27. http://dx.doi.org/10.4049/jimmunol.186.supp.56.27.
Der volle Inhalt der QuelleLi, Zilu, Daniel L. Clemens, Bai-Yu Lee, Barbara Jane Dillon, Marcus A. Horwitz und Jeffrey I. Zink. „Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia“. ACS Nano 9, Nr. 11 (09.10.2015): 10778–89. http://dx.doi.org/10.1021/acsnano.5b04306.
Der volle Inhalt der QuelleBar-On, Liat, Hila Cohen, Uri Elia, Shahar Rotem, Adi Bercovich-Kinori, Erez Bar-Haim, Theodor Chitlaru und Ofer Cohen. „Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung“. Vaccine 35, Nr. 50 (Dezember 2017): 7001–9. http://dx.doi.org/10.1016/j.vaccine.2017.10.053.
Der volle Inhalt der QuelleStinson, Elizabeth, Le'Kneitah P. Smith, Kelly Stefano Cole, Eileen M. Barry und Douglas S. Reed. „Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model“. Pathogens and Disease 74, Nr. 7 (09.08.2016): ftw079. http://dx.doi.org/10.1093/femspd/ftw079.
Der volle Inhalt der QuellePriyantha, M. A. R. „Francisella tularensis: a zoonotic pathogen among wild rodents and arthropods - a possible threat in future“. Sri Lanka Veterinary Journal 70, Nr. 1 (06.09.2023): 13–21. http://dx.doi.org/10.4038/slvj.v70i1.76.
Der volle Inhalt der QuelleSutherland, Marjorie D., Andrew W. Goodyear, Ryan M. Troyer, Jeffrey C. Chandler, Steven W. Dow und John T. Belisle. „Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia“. Vaccine 30, Nr. 33 (Juli 2012): 4977–82. http://dx.doi.org/10.1016/j.vaccine.2012.05.037.
Der volle Inhalt der QuelleKouadio, Koffi Isidore, Taro Kamigaki und Hitoshi Oshitani. „Strategies for Communicable Diseases Response After Disasters in Developing Countries“. Journal of Disaster Research 4, Nr. 5 (01.10.2009): 298–308. http://dx.doi.org/10.20965/jdr.2009.p0298.
Der volle Inhalt der QuelleClemens, Daniel L., Bai-Yu Lee, Sheba Plamthottam, Michael V. Tullius, Ruining Wang, Chia-Jung Yu, Zilu Li, Barbara Jane Dillon, Jeffrey I. Zink und Marcus A. Horwitz. „Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model“. ACS Infectious Diseases 5, Nr. 2 (27.11.2018): 281–91. http://dx.doi.org/10.1021/acsinfecdis.8b00268.
Der volle Inhalt der QuelleLee, Bai-Yu, Zilu Li, Daniel L. Clemens, Barbara Jane Dillon, Angela A. Hwang, Jeffrey I. Zink und Marcus A. Horwitz. „Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice“. Small 12, Nr. 27 (01.06.2016): 3690–702. http://dx.doi.org/10.1002/smll.201600892.
Der volle Inhalt der QuelleFuruya, Yoichi, Girish S. Kirimanjeswara, Sean Roberts und Dennis W. Metzger. „Increased Susceptibility of IgA-Deficient Mice to Pulmonary Francisella tularensis Live Vaccine Strain Infection“. Infection and Immunity 81, Nr. 9 (08.07.2013): 3434–41. http://dx.doi.org/10.1128/iai.00408-13.
Der volle Inhalt der QuelleRodriguez, Annette Rose, JiehJuen Yu, Ashlesh Murthy, M. Neal Guentzel, Karl E. Klose, James P. Chambers, Thomas G. Forsthurber, Michael T. Berton und Bernard P. Arulanandam. „Mast cells induce alternative activation and inhibit caspase-3 mediated apoptosis of Francisella tularensis infected macrophages (44.24)“. Journal of Immunology 182, Nr. 1_Supplement (01.04.2009): 44.24. http://dx.doi.org/10.4049/jimmunol.182.supp.44.24.
Der volle Inhalt der QuelleWest, T. Eoin, Mark R. Pelletier, Melanie C. Majure, Annalisa Lembo, Adeline M. Hajjar und Shawn J. Skerrett. „Inhalation of Francisella novicida ΔmglA causes replicative infection that elicits innate and adaptive responses but is not protective against invasive pneumonic tularemia“. Microbes and Infection 10, Nr. 7 (Juni 2008): 773–80. http://dx.doi.org/10.1016/j.micinf.2008.04.008.
Der volle Inhalt der QuelleBalagopal, Ashwin, Amanda Shearer MacFarlane, Nrusingh Mohapatra, Shilpa Soni, John S. Gunn und Larry S. Schlesinger. „Characterization of the Receptor-Ligand Pathways Important for Entry and Survival of Francisella tularensis in Human Macrophages“. Infection and Immunity 74, Nr. 9 (September 2006): 5114–25. http://dx.doi.org/10.1128/iai.00795-06.
Der volle Inhalt der QuelleHorzempa, Joseph, Dawn M. O'Dee, Robert M. Q. Shanks und Gerard J. Nau. „Francisella tularensis ΔpyrF Mutants Show that Replication in Nonmacrophages Is Sufficient for Pathogenesis In Vivo“. Infection and Immunity 78, Nr. 6 (12.04.2010): 2607–19. http://dx.doi.org/10.1128/iai.00134-10.
Der volle Inhalt der QuelleBarrigan, Lydia, Shraddha Tuladhar, Jason Brunton, Matthew Woolard, Ching-ju Chen, Divey Saini, Richard Frothingham, Gregory Sempowski, Thomas Kawula und Jeffrey Frelinger. „Altered host immune responses, not lowered growth, are the mechanism of attenuation of Francisella tularensis clpB (P3126)“. Journal of Immunology 190, Nr. 1_Supplement (01.05.2013): 186.10. http://dx.doi.org/10.4049/jimmunol.190.supp.186.10.
Der volle Inhalt der QuelleWyatt, Elliott V., Karina Diaz, Amanda Griffin, Jed Rasmussen, Deborah Crane, Bradley Jones und Catharine M. Bosio. „Optimal replication and suppression of inflammation by virulent Francisella tularensis is achieved through reprogramming of host glycolysis.“ Journal of Immunology 196, Nr. 1_Supplement (01.05.2016): 66.7. http://dx.doi.org/10.4049/jimmunol.196.supp.66.7.
Der volle Inhalt der Quelle